Advanced Kidney Cancer

The 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting held in Washington, DC between September 29^th and October 2^nd, 2024, was host to a presidential symposium of innovations in genitourinary cancers, specifically addressing the ‘renaissance’ of radiotherapy for renal cell carcinoma (RCC). Dr. Shankar Siva discussed whether stereotactic ablative radiotherapy (SABR) for the treatment of primary RCC is ready for ‘primetime’. Read More

Dr. Chiara Ciccarese presented the preliminary results of the randomized phase 2 TACITO trial, exploring fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma (mRCC). Read More

Dr. Xinan Sheng presented the results from the ETER100 phase III randomized, open-label study, exploring Anlotinib combined with anti-PD-L1 antibody Benmelstobart (TQB2450) versus sunitinib in first-line treatment of advanced renal cell carcinoma (RCC). Read More

The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 16^th, 2024 was host to a session focusing on rare genitourinary cancers. Dr. Pedro Barata discussed the current treatment paradigm of non-clear cell renal cell carcinoma (nccRCC). Read More

The 2024 ESMO annual meeting included a session on addressing uncertainties in the management of urothelial and renal cell carcinomas, featuring a presentation by Dr. Yohann Loriot discussing the role of rechallenge with the same class of agents in advanced disease. Dr. Loriot notes that this is an old question revisited with the coming of new drugs. Read More

The 2024 ESMO annual meeting included a session on addressing uncertainties in the management of urothelial and renal cell carcinomas, featuring a presentation by Dr. Begona Perez-Valderrama discussing how to build on standard therapies by assessing novel agents and promising combinations. Since 2010, there have been numerous FDA and EMA approvals of new agents in renal cell carcinoma, prostate cancer, and urothelial carcinoma: Read More

The 2024 ESMO annual meeting included a session on kidney cancer, featuring a discussant presentation by Dr. Manuela Schmidinger discussing three abstracts including “Tivozanib–Nivolumab vs Tivozanib Monotherapy in Patients with RCC Following 1 or 2 Prior Therapies including an Immune Checkpoint Inhibitor – Results of the Phase III TiNivo-2 Study” by Dr. Toni Choueiri, “Final analysis of the phase 3 LITESPARK-005 study of belzutifan versus everolimus in participants with previously treated advanced clear cell RCC” by Dr. Brian Rini, and “Prospective randomized phase II trial of Ipilimumab + Nivolumab versus standard of care in non-clear cell RCC: Results of the SUNNIFORECAST trial” by Dr. Lothar Bergmann. Read More

The 2024 ESMO annual meeting included a session on kidney and bladder cancer, featuring a discussant presentation by Dr. Jonathan Rosenberg discussing two abstracts including “BL-B01D1-201: BL-B01D1, an EGFR x HER3 Bispecific Antibody-drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma” presented by Dr. Dingwei Ye, and “NKT2152, a novel oral HIF-2α inhibitor, in participants with previously treated advanced clear cell RCC: Preliminary results of a Phase 1/2 study” presented by Dr. Eric Jonasch. Read More

The 2024 ESMO annual meeting included a session on kidney cancer, featuring a presentation by Dr. Eric Jonasch discussing preliminary results of a phase 1/2 study assessing NKT2152, a novel oral HIF-2α inhibitor, in patients with previously treated advanced clear cell RCC Read More

The 2024 ESMO annual meeting included a session on kidney cancer, featuring a presentation by Dr. Lothar Bergmann discussing results of the phase II SUNNIFORECAST trial assessing ipilimumab + nivolumab versus standard of care in non-clear RCC. Non-clear cell RCC is a rare and heterogeneous group of more than 20 histological and molecular-defined entities. Read More

The 2024 ESMO annual meeting included a session on kidney cancer, featuring a presentation by Dr. Brian Rini discussing the final analysis of the phase 3 LITESPARK-005 study of belzutifan versus everolimus in participants with previously treated advanced clear cell RCC. Belzutifan is a first-in-class oral HIF-2alpha inhibitor that blocks heterodimerization with HIF-1beta and downstream oncogenic pathways: Read More

The 2024 ESMO annual meeting included a session on kidney cancer, featuring a presentation by Dr. Toni Choueiri discussing results of the phase III TiNivo-2 trial assessing tivozanib + nivolumab versus tivozanib monotherapy in patients with RCC following 1 or 2 prior therapies including an immune checkpoint inhibitor. Immune checkpoint inhibitors are the cornerstone of the first line treatment of advanced metastatic RCC, however the optimal sequence in patients whose disease has progressed after treatment with immune checkpoint inhibitors is uncertain, leaving several unanswered questions: Read More

The 2024 SESAUA annual meeting featured a kidney cancer session and a presentation by Dr. Edouard Nicaise discussing the safety and efficacy of surgery in metastatic and non-metastatic renal cell carcinoma (RCC) with supradiaphragmatic tumor thrombus involving cardiac procedures. Invasion of the inferior vena cava (IVC) is a unique feature of RCC, and tumor thrombus extension into the supradiaphragmatic IVC carries high morbidity and mortality attributable to surgical complexity. Read More

Thomas Powles presented the patient-reported outcomes from the phase 3 LITESPARK-005 study of belzutifan versus everolimus in patients with previously treated advanced renal cell carcinoma (RCC). Read More

Ulka Vaishampayan delivered the discussant for the preceding two presentations: Subcutaneous nivolumab (NIVO SC) versus intravenous nivolumab in patients with previously treated advanced or metastatic clear cell renal cell carcinoma: Pharmacokinetics, efficacy, and safety results from CheckMate 67T and Belzutifan versus everolimus in participants with previously treated advanced renal cell carcinoma: Patient-reported outcomes in the phase 3 LITESPARK-005 study.

Read More

Saby George presented the late-breaking pharmacokinetics, efficacy, and safety results from CheckMate 67T comparing subcutaneous and intravenous nivolumab in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (RCC). Read More

Sophia Kamran discussed the role of radiation therapy for the management of RCC primary tumors and distant metastatic sites. Dr. Kamran noted that the ‘historical teaching’ is that radiation is not effective for RCC in either the primary or metastatic setting, with radiation primarily reserved for palliative purposes. But in contemporary practice, is RCC radioresistant?

Read More

The 2024 GU ASCO annual meeting featured an oral abstract renal cell carcinoma session and a presentation by Dr. Toni Choueiri discussing overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma. Read More

Dr. Andrea Apolo delivered the discussant for the preceding two late-breaking oral abstract presentations: EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab (EV+P) Vs Chemotherapy (Chemo) in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma (la/mUC), Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results from the phase 3 CheckMate 901 trial

 

Read More

During the 2023 ESMO annual congress, Dr. Neeraj Agarwal presented the results of the phase II LITESPARK-013 study that evaluated the safety and efficacy of two doses of belzutifan in patients with advanced renal cell carcinoma (RCC). Read More

Dr. Brian Rini kicked off the initial talk of the SUO session at the AUA 2023 Annual Meeting, focusing on the management of metastatic non-clear cell renal cell carcinoma (nccRCC). First, he focused on papillary renal cell carcinoma (RCC). Read More

The Presidential Symposium III at the ESMO Annual Congress, Dr. Chouieri presented highly awaited results from the COSMIC-313 trial, examining the role of triplet therapy with cabozantinib, nivolumab and ipilimumab as first-line treatment in patients with advanced renal cell carcinoma (aRCC). Read More

Following presentations from Dr. Camillo Porta discussing updated results from the CLEAR trial on outcomes of the combination of Lenvatinib and pembrolizumab as first-line therapy in advanced renal cell carcinoma (RCC) and from Dr. Grimm discussing a tailored approach using nivolumab either as monotherapy or in combination with ipilimumab in metastatic RCC, Dr. Young provided an invited discussion to contextualize these results in the Mini Oral session of the European Society for Medical Oncology (ESMO) Annual Congress focusing on non-prostate genitourinary cancers. Read More

At the ESMO Annual Congress focusing on non-prostate genitourinary cancers, Dr. Grimm presented the final results of the TITAN-RCC trial, assessing a tailored approach to systemic therapy in patients with metastatic renal cell carcinoma (mRCC). Read More

In the Mini Oral session of the ESMO Annual Congress focusing on non-prostate genitourinary cancers, Dr. Porta provided an updated analysis of the CLEAR trial examining the role of the combination of lenvatinib and pembrolizumab, as compared to sunitinib, as first-line therapy in advanced renal cell carcinoma (aRCC). Read More

The 2022 ASCO annual meeting featured a poster discussion session on kidney and bladder cancer, including a presentation by Dr. Tom Powles discussing an analysis of progression after first subsequent therapy in KEYNOTE-426, which tested pembrolizumab + axitinib versus sunitinib as first-line therapy for advanced clear cell RCC. Read More

The 2022 ASCO annual meeting featured a session on kidney and bladder cancer, including a presentation by Dr. Eric Jonasch discussing updated results of the LITESPARK-004 phase 2 study of belzutifan, an oral hypoxia-inducible factor 2α inhibitor (HIF-2α), for von Hippel-Lindau (VHL) disease. Read More

The 2022 American Urological Association (AUA) Annual Meeting included the Society of Urologic Oncology (SUO) session and a presentation by Dr. Daniel Shapiro discussing the role of cytoreductive nephrectomy in 2022. Read More

The 2022 International Kidney Cancer Symposium (IKCS) European Annual meeting included an oral abstract session and presentation by Dr. Will Ince discussing the real world impact of immune checkpoint inhibitors on survival in metastatic RCC. Read More

In the sixth session of the 2022 International Kidney Cancer Symposium (IKCS): Europe meeting focusing on later-lines of systemic therapy in advanced kidney cancer, Drs. Camillo Porta and Laurence Albiges debated the approach to second-line therapy in metastatic renal cell carcinoma (mRCC). Read More

In the sixth session of the 2022 International Kidney Cancer Symposium (IKCS): Europe meeting focusing on later lines of systemic therapy in advanced kidney cancer, Drs. Camillo Porta and Laurence Albiges debated the approach to second-line therapy in metastatic renal cell carcinoma (mRCC). Dr. Porta presented first, emphasizing evidence-based second line treatment approaches. Read More

In the fifth session of the 2022 International Kidney Cancer Symposium (IKCS): Europe meeting focusing on first-line systemic therapy in advanced kidney cancer (metastatic renal cell carcinoma, mRCC), Dr. Pickering presented the first side of a debate regarding treatment selection, defending the approach of immune checkpoint inhibition combined with tyrosine kinase inhibitor (IO/TKI). Read More

In the fifth session of the 2022 International Kidney Cancer Symposium (IKCS): Europe meeting focusing on first-line systemic therapy in advanced kidney cancer, Dr. Aristotelis Bamias presented the second side of the debate regarding treatment selection, defending the approach of dual immune checkpoint inhibition with nivolumab and ipilimumab. Read More

The 2022 International Kidney Cancer Symposium (IKCS) European Annual meeting included an oral abstract session and presentation by Dr. Bernard Escudier discussing nivolumab + ipilimumab + cabozantinib for previously untreated advanced renal cell carcinoma (RCC), which was a discontinued study arm in the phase 3 CheckMate 9ER trial. Read More

In Poster Session C on the third day of the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022 focused on Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers. In this session, Dr. Rha presented subgroup analyses of efficacy and safety from the CLEAR trial of Lenvatinib and pembrolizumab among East Asian patients with advanced renal cell carcinoma (aRCC). Read More

The 2022 GU ASCO Annual meeting included a renal cell carcinoma (RCC) session highlighting work from Dr. David Cella and investigators presenting results assessing HRQoL in previously untreated patients with advanced renal cell carcinoma in the CheckMate 9ER trial.  Read More

In an oral abstract Dr. Axel Bex presented results of the NeoAvAx study examining neoadjuvant avelumab and axitinib following nephrectomy for patients who are at high risk for recurrence. Read More

In an oral abstract Dr. Toni Choueiri presented 30-month follow-up from the KEYNOTE-564 trial of post-nephrectomy adjuvant pembrolizumab in patients with renal cell carcinoma (RCC). Read More

Dr. Martin Voss presented the PIVOT IO 011 study, a phase 1/2 study evaluating of bempegaldesleukin plus nivolumab and TKI versus nivolumab and TKI alone in patients with previously untreated advanced or metastatic RCC. Read More

Dr. Toni Choueiri presented the rationale and design of the TiNivo-2 trial, examining tivozanib with or without nivolumab in patients with renal cell carcinoma (RCC) who have progressed following one or two lines of therapy, one of which was an immune checkpoint inhibitor. Read More

Dr. Neil Shah and colleagues presented results of a real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma in the first-line setting.  Read More

The SUO 2021 annual meeting in Orlando, FL hosted a second State of the Art Lecture by Dr. Robert Dreicer, MD, MS, MACP, FASCO discussing adjuvant therapy for kidney cancer. Read More

The SIU 2021 annual meeting included a master class on advanced kidney cancer with a presentation by Dr. Kevin Lu discussing nephrectomy as part of the sequencing options in metastatic renal cell carcinoma (RCC) with the primary in place. Read More

At the 2021 International Kidney Cancer Symposium (IKCS): North America meeting, Dr. Barata presented their work examining gene expression profiling (GEP) in non-clear cell renal cell carcinoma. They employed DNA/RNA next-generation sequencing of tumor samples from the Caris Life Sciences lab. They defined molecular subgroups according to the criteria set out by Motzer et al. and examined 7 clusters.

Read More

The International Kidney Cancer Symposium 2021 annual hybrid meeting included a non-clear cell renal cell carcinoma (RCC) session and a presentation by Dr. Bradley McGregor discussing recent and future studies of systemic therapy for non-clear cell RCC. Read More

In a session of the 2021 International Kidney Cancer Symposium (IKCS): North America meeting focused on the role and effects of adjuvant immunotherapy in renal cell carcinoma (RCC) on subsequent first-line therapy, Dr. Choueiri provided an overview of his perspective of the future of adjuvant therapy in this disease space. Read More

In this presentation, Dr. Toni Choueiri discussed patient-reported outcomes (PROs) from KEYNOTE-564, a randomized phase 3 study of adjuvant Pembrolizumab versus placebo in patients with renal cell carcinoma (RCC). Read More

The ESMO 2021 annual meeting’s non-prostate cancer proffered paper session included a presentation by Dr. Naveen Vasudev discussing results of the phase II PRISM trial assessing nivolumab combination with alternatively scheduled ipilimumab in first-line treatment of advanced renal cell carcinoma (RCC). Read More

The ESMO 2021 virtual annual meeting’s non-prostate cancer session included a presentation by Dr. Yann Vano discussing the CABIR study of patients receiving cabozantinib-nivolumab versus nivolumab-cabozantinib after receiving a prior VEGFR TKI for metastatic clear cell RCC. Nivolumab and cabozantinib are two approved agents after a prior TKI in metastatic RCC patients. Read More

The ESMO 2021 annual meeting’s non-prostate cancer session included a presentation by Dr. Brian Rini discussing a new 3-arm phase 3 trial concept and design, which will randomize patients with advanced clear cell RCC in the first-line setting to either pembrolizumab + belzutifan + lenvatinib versus MK-1308A + lenvatinib versus pembrolizumab + lenvatinib. Read More

The ESMO 2021 virtual annual meeting’s non-prostate cancer session included a presentation by Dr. Robert Motzer discussing updated data from the CheckMate 214 trial with 5-years of follow-up. Read More

The ESMO 2021 annual meeting’s non-prostate cancer session included a presentation by Dr. Toni Choueiri discussing outcomes of subgroup analyses and a toxicity update among patients in the phase 3 CLEAR trial for advanced renal cell carcinoma (RCC). Read More

In this presentation, Dr. Toni Choueiri presented results from KEYNOTE-564, a study of adjuvant pembrolizumab administered for one year after complete surgical resection of clear cell RCC. The eligibility and study design are shown below. The primary endpoint was disease-free survival by investigator assessment.  Read More

The much anticipated ASCO 2021 annual program plenary session included a discussant presentation by Dr. Rana McKay providing her expertise on the recently presented KEYNOTE 564 phase 3 trial with her talk entitled “A Quantum Leap in Cancer Adjuvant Immunotherapy”. Read More

Building on the presentations from Dr. Linehan regarding the genetic causes of renal cell carcinoma (RCC) and from Dr. McDermott regarding current and future direction for immunotherapy in RCC, Dr. Srinivasan presented on challenges and emerging strategies for systemic therapy in kidney cancer.

Read More

The European International Kidney Cancer Symposium 2021 virtual meeting’s keynote lecture was provided by Dr. David McDermott discussing kidney cancer as a model for a curable neoplasm.  Read More

Dr. Vano discussed biomarker-driven trials. He first argued for the rationale of biomarker-driven trials based on the rationale that metastatic kidney cancer represents an incurable disease and current therapies have significant toxicity. He further emphasized that, based on drug development over the past two decades, there are many treatment options in mRCC that improve survival. Read More

The European International Kidney Cancer Symposium 2021 Virtual Meeting included a systemic therapy session and a presentation by Dr. Thomas Powles discussing tissue-based biomarkers for potential clinical adoption in renal cancer. Read More

To help guide treatment choices for those who progress on first-line therapy, Dr. Camillo Porta discussed modern therapeutic approaches in second-line and later therapies in a presentation at the European International Kidney Cancer 2021 Virtual Annual Meeting. Read More

Following presentations by Dr. Robert Motzer discussing results of the CLEAR study of lenvatinib plus pembrolizumab or everolimus versus sunitinib in first-line treatment of advanced renal cell carcinoma and by Dr. Sumanta Pal looking at the SWOG 1500 trial of sunitinib, cabozantinib, crizotinib, and savolitinib in patients with metastatic papillary renal cell carcinoma. Read More

The activity of tivozanib after axitinib has not been previously defined, and as such the activity of tivozanib after prior therapy types including axitinib is of clinical relevance. At the 2021 ASCO GU, Dr. Brian Rini and colleagues presented results of the TIVO-3 trial testing tivozanib in patients with advanced RCC who had progressed after prior axitinib treatment. Read More

The treatment landscape for first-line therapy among patients with metastatic renal cell carcinoma (mRCC) has changed dramatically over the past 2 years. In 2018, publication of the CheckMate214 data demonstrated a survival benefit for patients treated with nivolumab and ipilimumab compared with sunitinib in intermediate and poor-risk mRCC, ushering in the immunotherapy era for mRCC. Read More

Cabozantinib, nivolumab, and ipilimumab have been increasingly utilized for a number of genitourinary malignancies, most prominently in renal cell carcinoma. In a dose-escalation study, combinations of cabozantinib and nivolumab (CaboNivo) and cabozantinib, nivolumab, and ipilimumab (CaboNivoIpi) demonstrated promising efficacy and safety in a dose-escalation phase I study. Read More

In this state-of-the-art presentation, Dr. Toni Choueiri gave an overview of the management of advanced kidney cancer. Several years ago, before the era of immunotherapy, when vascular endothelial growth factor (VEGF) receptor inhibitors were compared and used to treated advanced kidney cancer patients, the median overall survival was only 13 months. Read More

Sunitinib was standard first line treatment for metastatic clear cell renal cell carcinoma (mccRCC) for many years until multiple clinical trials showed superior efficacy of various treatment combinations including nivolumab and ipilimumab in International Metastatic RCC Database Consortium (IMDC) intermediate or poor-risk disease. Read More

Barcelona, Spain (UroToday.com) Four large, randomized Phase 3 clinical trials (S-TRAC, ASSURE, PROTECT, and ATLAS) evaluated adjuvant VEGF tyrosine kinase inhibitors in patients with resected renal cell carcinoma (RCC). Read More

Barcelona, Spain (UroToday.com) The current standard for advanced localized renal cell carcinoma (RCC) is nephrectomy. Unfortunately, for better or worse, the series of adjuvant therapy Read More

Barcelona, Spain (UroToday.com) Dr. Marc-Oliver Grimm provided an overview of the many changes in the landscape for advanced renal cell carcinoma at the urogenital cancer treatment at a glance session. He started by highlight that the guidelines for advanced kidney cancer have been revamped recently Read More

Munich, Germany (UroToday.com) IMmotion 150 (Phase II) compared the efficacy of atezolizumab (atezo) plus bevacizumab (bev) with atezolizumab alone and sunitinib alone Read More